Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Mako Surgical offering nets $54.4 million: Robotic knee surgery device maker Mako Surgical nets $54.4 million from a secondary offering of 8.05 million shares of common stock at $7.25 each, completed Aug. 19. The proceeds are tabbed "to support commercialization, sales, marketing and general administrative activities" as well as R&D and working capital, the company explains. In February, the firm rolled out its "next generation" RIO Tactile Guidance System version 2.0 robotic arm and Restoris MCK bi-compartmental knee resurfacing implant. The Fort Lauderdale, Fla., firm, which previously offered versions of the technology for unicompartmental knee procedures, went public in February 2008 (1"The Gray Sheet" Dec. 8, 2008). Underwriters for the most recent offering are Piper Jaffray & Co. and Leerink Swann LLC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel